IL1B and astrocytoma (excluding glioblastoma): The selective CK2 inhibitor CX-4945 significantly reduced the IL-1β/TNF-α induced secretion of the inflammatory cytokines MCP-1 and IL-6 both in human primary astrocytes and U373 astrocytoma cells in a dose-dependent manner.